Phase Ib Study: Lenvatinib + Pembrolizumab in Unresectable Hepatocellular Carcinoma

Downloadable resource: current EGFR-targeted agents for advanced NSCLC with EGFR mutations, including exon 20 insertions, from Clinical Care Options (CCO)

Downloadable resource on active research and ongoing clinical trials in EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Downloadable resource on best practices for molecular testing of targetable biomarkers in advanced NSCLC (May 2022), from Clinical Care Options (CCO)

Gain expert pharmacist insight on the management of hemophilia A with factor and nonfactor replacement therapies

Justin Arnall, PharmD, BCOP Kayla Douglas, PharmD Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 24, 2022 Expired: May 23, 2023